A Mentor Who Helped Show the 'Way of the Future' in the Treatment of Early TNBC

Clinton Yam, MD

Disclosures

July 29, 2022

Clinton Yam, MD, reflects on the guidance that he received from an important mentor he had during his fellowship, Dr Stacy Moulder. Dr Yam recalls his mentor's strong advocacy and personalized response-adapted approach for patients with treatment-resistant triple-negative breast cancer (TNBC).

Dr Moulder's approach to treating early TNBC involves starting all patients on standard therapy and then conducting an early on-treatment response to better personalize disease management. This approach developed into the ARTEMIS clinical trial, among others, and is what Dr Yam considers to be the "way of the future" in the management of patients with early TNBC.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....